Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | PRAP1 | Q96NZ9 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.75 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.75 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.75 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.75 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.75 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.75 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.75 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.75 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.75 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.75 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.75 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.75 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.75 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd2461 SCHEMBL77012 | 1.00 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| Azd2461 SCHEMBL29361302 | 1.00 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22852674 | 0.97 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22852672 | 0.95 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL31311843 | 0.92 | PARP1 (0.85) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL76871 | 0.91 | PARP1 (0.84) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL87500 | 0.91 | PARP1 (0.84) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL22852677 | 0.91 | PARP1 (1.00) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL78156 | 0.91 | PARP1 (0.83) | PARP1PRAP1TNKSADORA1CDK6 | |
| SCHEMBL86912 | 0.91 | PARP1 (0.82) | PARP1PRAP1TNKSADORA1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129163-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2025-04-24 | — | — | US | claimed |
| US-20250114450-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | AKESO BIOPHARMA, INC. (CN) | 2025-04-10 | — | — | US | claimed |
| CN-118510533-A | Cancer diagnostic method using ephrin B2 expression | 血管基因治疗公司 | 2024-08-16 | — | — | CN | claimed |
| EP-4398928-A1 | DIAGNOSTIC METHODS FOR CANCER USING EPHRINB2 EXPRESSION | Vasgene Therapeutics Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| US-20240150848-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-09 | — | — | US | claimed |
| CN-113786409-B | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | 甫康（上海）健康科技有限责任公司 | 2024-04-02 | — | — | CN | claimed |
| EP-4321537-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | Akeso Biopharma, Inc. (CN) | 2024-02-14 | — | — | EP | claimed |
| EP-4301879-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | Board of Regents, The University of Texas System (US) | 2024-01-10 | — | — | EP | claimed |
| WO-2023246247-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中山康方生物医药有限公司 | 2023-12-28 | — | — | WO | claimed |
| CN-117257934-A | Pharmaceutical composition and use thereof | 中山康方生物医药有限公司 | 2023-12-22 | — | — | CN | claimed |
| US-20220319704-A1 | METHODS FOR CHARACTERIZING AND TREATING A CANCER TYPE USING CANCER IMAGES | TESARO, INC. (US) | 2022-10-06 | — | — | US | claimed |
| CN-115068603-A | Pharmaceutical combination containing anti-PD-1-anti-VEGFA bispecific antibody and application thereof | 中山康方生物医药有限公司 | 2022-09-20 | — | — | CN | claimed |
| WO-2022188832-A1 | PHARMACEUTICAL COMBINATION CONTAINING ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | 中山康方生物医药有限公司 | 2022-09-15 | — | — | WO | claimed |
| WO-2022187554-A1 | METHODS AND SYSTEMS FOR DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE CARCINOMAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-09-09 | — | — | WO | claimed |
| US-11382903-B2 | Cancer therapy | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2022-07-12 | — | — | US | claimed |
| US-11311548-B2 | Cancer therapy | ASLAN PHARMACEUTICALS PTE. LTD. (SG) | 2022-04-26 | — | — | US | claimed |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | KARUS THERAPEUTICS LIMITED (GB) | 2022-04-05 | — | — | US | claimed |
| EP-3966782-A2 | METHODS FOR CHARACTERIZING AND TREATING A CANCER TYPE USING CANCER IMAGES | Tesaro, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| WO-2022020218-A1 | DIAGNOSTIC METHODS FOR CANCER USING AXL DECOY RECEPTORS | ARAVIVE INC (US) | 2022-01-27 | — | — | WO | claimed |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | SENHWA BIOSCIENCES, INC. (TW) | 2022-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382903-B2 | Cancer therapy | DHODH, MCL1, DOHH | PARP1 506/4885PRAP1 488/4885TNKS 1171/4885 |
| US-11311548-B2 | Cancer therapy | DHODH, MCL1, DOHH | PARP1 506/4885PRAP1 488/4885TNKS 1171/4885 |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | PARP1 33/4885PRAP1 1484/4885TNKS 204/4885 |
| US-11229654-B2 | Combination therapy of tetracyclic quinolone analogs for treating cancer | CXCR4, CXCR6, TLR7 | PARP1 1475/4885PRAP1 3629/4885TNKS 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.